RxDoctor Payments Data

Jeffrey Thatcher, MD

Internal Medicine · Telford, PANPI 1871547216

Payments from drug & device makers

$355in general payments, 2019–2025

Across 13 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$115
  • AbbVie$75
  • Pfizer$62
  • GSK$41
  • Amgen$39
  • Abbott$23

What the payments were for

  • Food & beverage$355100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech USA, Inc.1$115
AbbVie3$75
Pfizer3$62
GSK3$41
Amgen2$39
Abbott1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$355 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$109,475
Medicare patients
265
Services billed
2,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$35,240
XareltoRivaroxaban19$18,575
JardianceEmpagliflozin14$9,423
Levothyroxine Sodium209$2,519
Atorvastatin Calcium246$2,177
Escitalopram Oxalate161$1,999
Metoprolol Succinate100$1,774
Amlodipine Besylate246$1,703
Simvastatin145$1,445
Omeprazole131$1,339
Tamsulosin Hcl81$1,270
Gabapentin101$1,206
Famotidine178$1,204
Pravastatin Sodium57$1,067
Esomeprazole Magnesium15$1,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$35,24027 claims
AbbVieSynthroid$75$74623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Telford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →